BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22517371)

  • 1. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
    Morris PG; Ulaner GA; Eaton A; Fazio M; Jhaveri K; Patil S; Evangelista L; Park JY; Serna-Tamayo C; Howard J; Larson S; Hudis CA; McArthur HL; Jochelson MS
    Cancer; 2012 Nov; 118(22):5454-62. PubMed ID: 22517371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.
    Ulaner GA; Eaton A; Morris PG; Lilienstein J; Jhaveri K; Patil S; Fazio M; Larson S; Hudis CA; Jochelson MS
    Cancer Med; 2013 Oct; 2(5):725-33. PubMed ID: 24403238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
    Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM
    AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H; Wroblewski K; Pu Y
    Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of PET/CT in lung cancer: retrospective analysis of 47 patients].
    de Guevara DL; Fuentes A; Fariña C; Corral C; Pefaur R
    Rev Med Chil; 2013 Jan; 141(1):41-8. PubMed ID: 23732413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of SUV
    Diao W; Tian F; Jia Z
    Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer.
    Oh JK; Chung YA; Kim YS; Jeon HM; Kim SH; Park YH; Chung SK
    Biomed Mater Eng; 2014; 24(1):1173-84. PubMed ID: 24212011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin.
    Algin E; Ozet A; Gumusay O; Cetin B; Akdemir UO; Benekli M; Coskun U; Uner A; Kapucu O; Buyukberber S
    Ann Nucl Med; 2014 Nov; 28(9):891-6. PubMed ID: 25270711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
    De Cicco C; Gilardi L; Botteri E; Fracassi SL; Di Dia GA; Botta F; Prisco G; Lombardo D; Rotmensz N; Veronesi U; Paganelli G
    Breast; 2013 Feb; 22(1):39-43. PubMed ID: 22704459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining PET standardized uptake value threshold for tumor delineation with metastatic lymph nodes in head and neck cancer.
    Suzuki O; Nishiyama K; Morimoto M; Hashiguchi H; Tanaka K; Nakajima A; Nakamura S; Yoshino K
    Jpn J Clin Oncol; 2012 Jun; 42(6):491-7. PubMed ID: 22547728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography/computed tomography for lung cancer staging].
    Ladrón de Guevara H D; Furnaro L F; Yévenes A S; Clavero R JM; Lazo P D; Rodríguez D P; Piottante B A; Pefaur D R; Pardo B C
    Rev Med Chil; 2015 Jan; 143(1):22-9. PubMed ID: 25860265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
    Satoh Y; Nambu A; Ichikawa T; Onishi H
    BMC Cancer; 2014 Jul; 14():525. PubMed ID: 25048880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.